Zopa Retreatment and Vector Shedding in Adults With RRP

ClinicalTrials.gov ID

NCT06538480

Lead Sponsor

Precigen, IncINDUSTRY

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 4

Enrollment

30Estimated

Last Update Posted

Dec 15, 2025Actual

Start Date

Jul 11, 2024Actual

Primary Completion Date

Dec 2, 2027Estimated

Completion Date

Dec 2, 2028Estimated

Official Title

Open-Label Study of Zopapogene Imadenovec Retreatment and Vector Shedding Evaluation in Adult Patients With Recurrent Respiratory Papillomatosis

Brief Summary

This open-label study evaluates safety, vector shedding, and retreatment efficacy of Zopapogene imadenovec (Zopa) in adults with recurrent respiratory papillomatosis (RRP). Two cohorts will be enrolled (n=30): Cohort 1 to assess the magnitude and duration of adenoviral vector shedding in urine, feces, skin, and nasal tissue; Cohort 2 to assess the complete response rate following retreatment.

• Recurrent Respiratory Papillomatosis
• Papillomavirus Infection
• Papillomaviridae

• Zopapogene imadenovec (Zopa)

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Key Inclusion Criteria:

• Age 18 years and older.
• Clinical diagnosis of recurrent respiratory papillomatosis with histological confirmation of papilloma.
• Cohort 1: Treatment-naïve with respect to Zopa.
• Cohort 2: Received a minimum of four administrations of Zopa at 5 × 10^11 PU per injection and require clinically indicated debulking procedures.
• Presence of laryngotracheal papillomas accessible for endoscopic cleanout.
• ECOG performance status 0 or 1.
• Sexually active participants of reproductive potential must agree to use contraception during treatment and for 120 days for males and 6 months for females after last dose.
• Ability to understand and sign informed consent.

Key Exclusion Criteria:

• Conditions or therapies that increase risk or interfere with participation per investigator judgment.
• Systemic corticosteroids >10 mg prednisone equivalent or other immunosuppressive medications within 14 days prior to dosing.
• Other systemic RRP treatments or investigational agents within 30 days.
• History of heparin-induced thrombocytopenia or vaccine-induced thrombotic thrombocytopenia.
• Active uncontrolled HIV, hepatitis B, or hepatitis C infection.
• Pregnant or nursing women.
• Known allergy to any study drug component.

Primary Purpose

Treatment

Allocation

Non-Randomized

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Precigen, IncINDUSTRY

gibsonrk@ucmail.uc.edu513-558-1719

• Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis

  NCT04724980

  Active, not recruitingInterventionalPhase 1Phase 2Updated Jun 11, 2025
• Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

  NCT05797246

  Active, not recruitingInterventionalPhase 2Updated Aug 31, 2026
• INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)

  NCT04398433

  CompletedInterventionalPhase 1Phase 2Updated Apr 14, 2026
• Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)

  NCT07756840

  Not yet recruitingInterventionalPhase 2Updated Sep 11, 2026
• Avelumab for People With Recurrent Respiratory Papillomatosis

  NCT02859454

  CompletedInterventionalPhase 2Updated Nov 2, 2021
• Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients

  NCT07317154

  RecruitingInterventionalPhase 1Updated Jul 10, 2026